PCN30 - Medical Cost Estimation for Elderly Acute Myeloid Leukemia (Aml) Using Real World Data in Japan

Abstract

The treatment goal in AML is complete response (CR). However, elderly AML patients are known as the population of poor response to the available treatment in Japan. In this approach, we aim to estimate the treatment related cost for elderly AML in Japan. Monthly medical costs in non-remission, remission and progression disease states are estimated from acute care hospital data in Japan (Medical Data Vision). We define the condition by using the administration pattern of cytarabine (standard treatment for elderly AML in Japan) and the bone marrow aspiration was used for the confirmation and diagnosis of response and relapse as trigger of the events. Based on the pattern of cytarabine administration in the elderly AML patients, estimated medical cost in remission is about 20-30% of non-remission or relapse states. In patients with non-remission or progression disease states, blood derivative and antibiotics associated with blood transfusions are the highest portion of the medical costs. In addition, medical cost in hospitalized patients for AML increase as the condition proceeds to the terminal. In this survey, we found the potential usability of Japan real world database to estimate the medical cost in remission, non-remission and progression state from the pattern of standard treatment (i.e. cytarabine). CR in AML patients is a therapeutic goal from clinical standpoint, and at the same time, it is suggested that maintaining the CR state can contribute to lower the medical cost